Influence of Adipose Mesenchymal Stem Cell-Derived Exosomes on the Th2/Treg Cells in Peripheral Blood of the Patients with Allergic Rhinitis and its Mechanism.
Han F., Xu X., Wang Y.
Prospective Study with a reported sample of 30, published in Am J Rhinol Allergy (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Am J Rhinol Allergy (2025)
- Country
- United States
- Reported sample size
- 30
- Source database
- PubMed
- PMID
- 41335007
- DOI
- 10.1177/19458924251401732
Abstract (original English)
BackgroundAt present, there are many therapeutic regimens for allergic rhinitis (AR), but their therapeutic effects are not better. Therefore, it is a focus to find new therapeutic targets by exploring AR immune regulation.ObjectiveTo explore the possible mechanism that adipose mesenchymal stem cell-derived exosomes (AMSC-exos) regulate the balance of Th2/Treg cells by mTOR pathway in AR patients.MethodsThirty patients with AR and 30 patients with deviated nasal septum alone were selected as AR group and control group. From each patient, 10 ml of peripheral blood were collected for determining the levels of blood plasma IL-4 and TGF- β as well as protein levels of p-PI3K (P85), p-AKT (Ser473), p-mTOR (Ser2448) and p-p70S6K (Thr389) in peripheral blood mononuclear cells (MCs) and the proportions of Th2 and Treg cells. And then MCs from AR patients were divided into two groups. One group was as AR cell group. Another group was co-cultured with AMSC-exos and served as AR cell + exos group. The levels of IL-4 and TGF- β in supernatant, the protein levels of p-PI3K (P85), p-AKT (Ser473), p-mTOR (Ser2448) and p-p70S6K (Thr389) in MCs and the proportions of Th2 and Treg cells were also determined.ResultsThe levels of p-PI3K (P85), p-AKT (Ser473), p-mTOR (Ser2448) and p-p70S6K (Thr389), the IL-4 level and the proportion of Th2 cells were significantly higher in the AR group than in the
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.